Conclusions
DISEASE, PATHOPHYSIOLOGY
As was the case for all trials initiated early in the pandemic, our study was designed based on an incomplete understanding of the disease, scant clinical evidence, and an evolving viral pathophysiology [The pandemic has highlighted the need for a more robust, global clinical research infrastructure, agile enough to withstand unexpected emergencies. COVID-19 trials have demonstrated researchers’ adaptability and innovative thinking and the capacity to rapidly introduce a range of innovations. These have evolved to establish more modern and efficient processes for conducting all clinical trials. Also, applying these measures more broadly will protect clinical research efforts during future pandemics.